drugset / Trial / NCT04502706
Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).
Timeline
- Start
- 2020-11-17
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
Outcome
Outcome not reported
Stopped: “Sponsor's decision to discontinue development of this molecule”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EPACMARSTOBART | Monoclonal antibody | 10 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 30 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 100 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 300 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 2000 mg | Intravenous |
| Subject | EPACMARSTOBART | Monoclonal antibody | 3000 mg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |